Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer

Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts

“…Recent advances in chemotherapy have yielded limited improvement in the prognosis for patients with lung cancer and the 5-year survival rate for all combined disease stages remains about 15%. For this reason, newer therapies such as those that inhibit actions of vascular or non-vascular growth factors [3][4][5] are of special interest in this group of patients. The two most prevalent histological types of lung carcinoma, categorized by the size and appearance of the malignant cells, are non-small cell (NSCLC) and small cell lung carcinoma [6].…”

Prognosis of Metastatic Carcinoma of the Lung in the Bevacizumab Era: Comparison Between the Major Histologic Types of Lung Cancer

“…Bevacizumab, an antibody against vascular endothelial growth factor [1] that received FDA approval for primary treatment of advanced non-squamous nonsmall-cell lung carcinoma in October 2006 [2][3][4], is part of the new family of anti-angiogenesis drugs [14]. Bevacizumab is used in association with platinumbased chemotherapy regimens [2,[5][6][7][8][9].…”

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians

“…RECIST criteria have important limitations in assessing the efficacy of anti-angiogenic therapy either as monotherapy or in combination with cytotoxic drugs, as evidenced by recent studies in various tumors [10][11][12]. In fact, antivascular targeted therapy have a marginal effect on tumor shrinkage, but cause necrosis, cavitation and bleeding of the tumor [13][14][15].…”